Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,855.00    160.00 (2.39%)
Bid:
6,850.00
Ask:
6,865.00
Spread: 15.00 (0.219%)
Market Cap: £5.06b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

7 Nov 2012 07:00

RNS Number : 4867Q
Spirax-Sarco Engineering PLC
07 November 2012
 



News Release

 

Wednesday 7th November 2012

INTERIM MANAGEMENT STATEMENT

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2012 to 6th November 2012.

 

Trading

In the four months ended 31st October, organic sales increased 6%, ahead of the rate of growth reported in the first half year. Notably, Asia Pacific and Watson-Marlow achieved strong double-digit sales growth in the period, followed by a more modest advance in the Americas and slightly reduced sales in our Europe, Middle East and Africa (EMEA) segment. Sales in sterling were ahead 2% in the first ten months of 2012, after including the impact of unfavourable currency movements and two small disposals last year.

 

As anticipated, our trading performance in the four months ended 31st October improved with operating profit 8% ahead at constant currency. Better results were particularly evident in Watson-Marlow, where the planned increases in R&D and market development costs in the first half year are unwinding in the second half. Results also improved in EMEA, as the cost base in Europe is being progressively lowered and the profitability of our Supply operations increased. For the ten months ended 31st October 2012, operating profit was therefore 2% ahead of last year at constant currency, compared with a decline of 3% for the first half year.

 

Financial position

We continue to operate with a strong balance sheet and are steadily reducing and rebalancing our stock position in Europe, although this continues to have a negative impact on the factory loading in our main manufacturing plants in the UK and France. Net cash balances at the end of October 2012 increased to £43m compared with £9m at 30th June 2012, although the interim dividend of £12m will be paid on 9th November. There were no significant events or transactions during the period that resulted in a material impact on the financial position of the Group. The principal risks and uncertainties remain those set out on pages 26 and 27 of the 2011 Annual Report.

 

Outlook

Global macro-economic conditions have weakened in recent months as reflected in slowing rates of GDP growth and industrial output in most geographic regions. Trading conditions in many of our markets have, however, remained more resilient and we have not seen softening in underlying demand. The Group has a favourable weighting to defensive industries such as food & beverage, pharmaceuticals and health care, and maintenance spending by our customers has continued to be positive, even against the deterioration in economic conditions.

 

Our business has other resilient characteristics due to our diverse geographic, industry, customer and product spread, and the large proportion of our sales that derive from maintenance or operating spend by our customers. We are seeing the improvements in our Supply organisation from the site consolidation in the UK and from the previously announced cost reduction programme in Europe, which should be complete by the year-end.

 

Although our forward visibility remains short and we are not immune to a worsening in our markets, which can be reflected fairly quickly in our mid-cycle business, the Board continues to expect the Group to make progress for the full year.

 

 

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note

All references above are to adjusted trading results that exclude non-operational items, including the previous announced restructuring costs, amortisation of acquisition-related intangible assets and acquisition and disposal costs.

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBUGGBGDL
Date   Source Headline
2nd Aug 20238:00 amRNSBoard Appointment
1st Aug 20239:09 amRNSDirector/PDMR Shareholding
27th Jul 20239:30 amRNSChange in Director Details
26th Jun 202310:00 amRNSNotice of Investment Seminar
22nd Jun 20232:03 pmRNSHolding(s) in Company
22nd Jun 20237:00 amRNSKyoto Investment and Partnership Agreement
14th Jun 202310:42 amRNSHolding(s) in Company
9th Jun 20235:45 pmRNSHolding(s) in Company
24th May 20232:46 pmRNSHolding(s) in Company
10th May 20233:23 pmRNSResult of AGM
10th May 20237:00 amRNSAGM Trading Update
16th Mar 20234:22 pmRNSDirector/PDMR Shareholding
16th Mar 20239:00 amRNSDirector/PDMR Shareholding
15th Mar 20234:12 pmRNSDirector/PDMR Shareholding
15th Mar 20239:53 amRNSDirector/PDMR Shareholding
15th Mar 20239:48 amRNSHolding(s) in Company
13th Mar 20231:31 pmRNSDirector/PDMR Shareholding
13th Mar 202312:22 pmRNSDirector/PDMR Shareholding
9th Mar 20237:00 amRNS2022 Full Year Results
8th Mar 20233:09 pmRNSChange of Director Details
21st Feb 202310:32 amRNSHolding(s) in Company
31st Jan 20239:30 amRNSBoard Changes
30th Jan 20236:04 pmRNSHolding(s) in Company
23rd Dec 202210:31 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSCompletion of the Acquisition of Durex Industries
17th Nov 20227:00 amRNSTrading Statement
27th Oct 20224:24 pmRNSDirector/PDMR Shareholding
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20227:00 amRNSCompletion of the acquisition of Vulcanic
28th Sep 20227:00 amRNSAcquisition of US Thermal Energy Specialist
6th Sep 202212:41 pmRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNS2022 Half Year Results
25th Jul 20227:30 amRNSVulcanic Acquisition Agreement Executed
4th Jul 202211:04 amRNSAmendment to 0126R - Director/PDMR Shareholding
4th Jul 20227:30 amRNSExclusive negotiations to acquire Vulcanic
1st Jul 202210:37 amRNSDirector/PDMR Shareholding
29th Jun 20227:00 amRNSInvestor Seminar
22nd Jun 20227:00 amRNSDirector/PDMR Shareholding
22nd Jun 20227:00 amRNSDirector/PDMR Shareholding
20th Jun 20227:00 amRNSDirector/PDMR Shareholding
23rd May 202210:48 amRNSElectric Thermal Solutions Business Update
23rd May 20229:08 amRNSDirector/PDMR Shareholding
11th May 20223:02 pmRNSResult of AGM
11th May 20227:00 amRNSAGM Trading Update
19th Apr 20223:10 pmRNSDirector/PDMR Shareholding
14th Apr 202212:00 pmRNSChange of Director Details
21st Mar 202210:10 amRNSDirector/PDMR Shareholding
17th Mar 20228:30 amRNSDirector/PDMR Shareholding
15th Mar 20223:00 pmRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNS2021 Full Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.